Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Motesanib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Motesanib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Nadofaragene Firadenovec |
Non-Replicating Adenoviral Vector Delivering Interferon Alfa-2b | Solid Tumour | ||
|
Molecule
Nadofaragene Firadenovec
Therapeutic Category
Immunotherapy (Gene Therapy)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Non-Replicating Adenoviral Vector Delivering Interferon Alfa-2b |
||||
Naporafenib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Naporafenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Naratuximab Emtansine |
ADC | Hematologic | ||
|
Molecule
Naratuximab Emtansine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Navitoclax |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
Navitoclax
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
Navtemadlin |
MDM2 Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Navtemadlin
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
||||
Naxitamab |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Naxitamab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Necitumumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Necitumumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Nemvaleukin Alfa |
Interferon / Interleukin | Both (Solid & Hematologic) | ||
|
Molecule
Nemvaleukin Alfa
Therapeutic Category
Immunotherapy (Cytokine)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Interferon / Interleukin |
||||
Neratinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Neratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Nimotuzumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Nimotuzumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Nintedanib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Nintedanib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
MotesanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
Nadofaragene FiradenovecImmunotherapy (Gene Therapy) |
|
|
Therapeutic Category
Immunotherapy (Gene Therapy)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Non-Replicating Adenoviral Vector Delivering Interferon Alfa-2b |
|
NaporafenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
Naratuximab EmtansineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
NavitoclaxTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
NavtemadlinTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
|
NaxitamabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
NecitumumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
Nemvaleukin AlfaImmunotherapy (Cytokine) |
|
|
Therapeutic Category
Immunotherapy (Cytokine)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Interferon / Interleukin |
|
NeratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
NimotuzumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
NintedanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|